A financial fundamental analysis of the pharma company . This covers the growth analysis and piotroski analysis to identify accounting strength. More details can be found in the paid version of the report. Lots more @ goodinvestory.com

1. BSE Code : 506170
NSE Code :
Sector : PHARMACEUTICALS
Report date : Thu Apr 24 06:53:37 EDT 2014
Industry overview
Market Cap
Market Cap is the price of
all the outstanding
common shares if we were
to buy it all at the current
price
4.74 Cr
The benchmark company
Sun Pharma in the
pharmaceuticals sector is
27430 times the size of
Hiran Orgochem
Ultra Small Caps are a
choice for people who can
handle very high
volatility/risk with very low
liquidity
1

2. Stock Analysis
Growth Analysis
Companies that have grown historically are more likely to exibit similar growth in the future. Read
the trends in the 4 year annualized profit growth, book value growth and sales growth shown
below:
How good are the returns?
RoE is the speed at which the company might grow without sorting to additional fund raising.
RoCE is the growth speed, if the company used all the assets, including loans/preference shares.
The 2-year and 4-year values give a reasonable assurance about the growth sustenance.
KEY
KEY
2

3. Piotroski Score
Seperate Winners from Losers
The Piotroski scoring system is a nine point system to determine the strength of a firm's financial
position. The score was developed by an accounting professor out of Chicago named Joseph
Piotroski. If it scores an 8 or 9, then the fundamentals are great for the stock.
Score: 2/9
3

4. DISCLAIMER
This report is prepared by the good.inve.story. software and is not prepared by an
actual person who has a CFA or any other certification.
good.inve.story. is still in BETA mode. So, please let us know if you find any errors.
We would love to hear from you.
This report is based on information obtained from public sources and sources
believed to be reliable, but no independent verification has been made nor is its
accuracy or completeness guaranteed.
This report is not an advisory to buy or sell. Please buy only if you think, this is the
right company at the right price and sell only if you don’t see any potential for
upside.
get more @ goodinvestory.com
4